Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?

Cancer

Volumn 121, Issue 15, 2015, Pages 2562-2569

  Sacher, Adrian G ^a,b,c   Le, Lisa W ^a   Lau, Anthea ^a   Earle, Craig C ^c,d   Leighl, Natasha B ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

chemotherapy; health services; metastatic; non small cell lung cancer (NSCLC); systemic therapy; treatment patterns

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; CANADA; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL PRACTICE; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PRESCRIPTION; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG PRESCRIPTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ONTARIO; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 84937516875     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29386     Document Type: Article

References (26)

1. Le Chevalier T, Brisgand D, Douillard JY, et al., Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994; 12: 360-367.
2. Shepherd FA, Ramlau R, Mattson K, et al., Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 2095-2103.
3. Belani CP, Pereira JR, von PJ, et al., Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer. 2006; 53: 231-239.
4. Hanna N, Shepherd FA, Fossella FV, et al., Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589-1597.
5. Scagliotti GV, Parikh P, von PJ, et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
6. Rosell R, Gatzemeier U, Betticher DC, et al., Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002; 13: 1539-1549.
7. Schiller JH, Harrington D, Belani CP, et al., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-98.
8. Ardizzoni A, Boni L, Tiseo M, et al., Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007; 99: 847-857.
9. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al., Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123-132.
10. Ramsey S, Howlader N, Etzioni R, et al., Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from Surveillance, Epidemiology and End Results-Medicare. J Clin Oncol. 2004; 22: 4971-4978.
11. Lang K, Marciniak M, Faries D, et al., Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer. 2009; 63: 264-270.
12. Owonikoko TK, Ragin C, Chen Z, et al., Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer. Oncologist. 2013; 18: 600-610.
13. Weiss GJ, Langer C, Rosell R, et al., Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006; 24: 4405-4411.
14. Quoix E, Zalcman G, Oster JP, et al., Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer. Lancet. 2011; 378: 1079-1088.
15. Salloum R, Smith T, Jensen G, et al., Survival among NSCLC patients with poor performance status after first-line chemotherapy. Lung Cancer. 2012; 77: 545-549.
16. Maemondo M, Minegishi Y, Inoue A, et al., First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012; 7: 1417-1422.
17. Sacher A, Le L, Leighl N, Coate L., Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? J Thorac Oncol. 2013; 8: 366-368.
18. Scagliotti G, Hanna N, Fossella F, et al., The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009; 14: 253-263.
19. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 2012: 1975-2009.
20. Siegel R, Naishadham D, Jemal A., Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
21. Camidge DR, Kono SA, Lu X, et al., Anaplastic lymphoma kinase gene rearrangements in NSCLC are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011; 6: 774-780.
22. Shaw AT, Kim DW, Nakagawa K, et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: 2385-2394.
23. Berge EM, Lu X, Maxson D, et al., Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive NSCLC. Clin Lung Cancer. 2013; 14: 636-643.
24. Hillner BE, McDonald MK, Desch CE, et al., A comparison of patterns of care of NSCLC patients in a younger and Medigap commercially insured cohort. Cancer. 1998; 83: 1930-1937.
25. Noonan K, Tong KM, Laskin J, et al., Referral patterns in advanced NSCLC: impact on delivery of treatment and survival in a contemporary population based cohort. Lung Cancer. 2014; 86: 344-349.
26. National Lung Cancer Screening Trial Research Team. Reduce lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.